Your browser doesn't support javascript.
loading
Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria.
Curto-Barredo, L; Spertino, J; Figueras-Nart, I; Expósito-Serrano, V; Guilabert, A; Melé-Ninot, G; Cubiró, X; Bonfill-Ortí, M; Garcias-Ladaria, J; Villar, M; García-Navarro, X; Bielsa-Marsol, I; Vilavella, M; Aparicio, G; Baliu-Piqué, C; Álvarez, A; Lamas-Domenech, N; Duran-Jordà, X; Serra-Baldrich, E; Giménez-Arnau, A.
Affiliation
  • Curto-Barredo L; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Spertino J; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Figueras-Nart I; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Expósito-Serrano V; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Guilabert A; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Melé-Ninot G; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Cubiró X; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Bonfill-Ortí M; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Garcias-Ladaria J; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Villar M; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • García-Navarro X; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Bielsa-Marsol I; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Vilavella M; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Aparicio G; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Baliu-Piqué C; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Álvarez A; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Lamas-Domenech N; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Duran-Jordà X; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Serra-Baldrich E; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
  • Giménez-Arnau A; Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona, (UAB) - Dermatology, Barcelona, Catalunya, Spain.
Br J Dermatol ; 179(1): 210-212, 2018 07.
Article in En | MEDLINE | ID: mdl-29368377
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urticaria / Chronic Disease / Anti-Allergic Agents / Omalizumab Type of study: Observational_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Br J Dermatol Year: 2018 Type: Article Affiliation country: Spain
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urticaria / Chronic Disease / Anti-Allergic Agents / Omalizumab Type of study: Observational_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Br J Dermatol Year: 2018 Type: Article Affiliation country: Spain